MF1 Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
CANbridge Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.011 |
| 52 Week High | HK$0.11 |
| 52 Week Low | HK$0.011 |
| Beta | -0.52 |
| 1 Month Change | -15.38% |
| 3 Month Change | -65.08% |
| 1 Year Change | -89.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -97.11% |
Recent News & Updates
Recent updates
Shareholder Returns
| MF1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -12.0% | 5.5% | 1.2% |
| 1Y | -89.5% | -3.7% | 10.1% |
Return vs Industry: MF1 underperformed the German Biotechs industry which returned -5.6% over the past year.
Return vs Market: MF1 underperformed the German Market which returned 9.4% over the past year.
Price Volatility
| MF1 volatility | |
|---|---|
| MF1 Average Weekly Movement | 26.0% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MF1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MF1's weekly volatility has increased from 20% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 93 | James Qun Xue | www.canbridgepharma.com |
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Livmarli, an oral, minimally-absorbed, reversible IBAT inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also engages in the development of CAN008, a CD95-Fc fusion protein that is in Phase 2/3 clinical trial for the treatment of glioblastoma multiforme; CAN106, an anti-C5 mAb that has completed Phase I clinical trial for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human enzyme replacement therapy (ERT) that is in Phase 2/3 clinical trials for gaucher disease.
CANbridge Pharmaceuticals Inc. Fundamentals Summary
| MF1 fundamental statistics | |
|---|---|
| Market cap | €6.31m |
| Earnings (TTM) | -€54.01m |
| Revenue (TTM) | €13.85m |
0.5x
P/S Ratio-0.1x
P/E RatioIs MF1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MF1 income statement (TTM) | |
|---|---|
| Revenue | CN¥104.61m |
| Cost of Revenue | CN¥37.69m |
| Gross Profit | CN¥66.92m |
| Other Expenses | CN¥474.87m |
| Earnings | -CN¥407.94m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 63.97% |
| Net Profit Margin | -389.95% |
| Debt/Equity Ratio | -16.3% |
How did MF1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 11:21 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CANbridge Pharmaceuticals Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |
| Yue-Kwong Lui | Jefferies LLC |
| Sean Wu | Morgan Stanley |